Half of people stop taking popular weight-loss drug within a year, study finds

The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight. However, a new population-wide study presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD), Vienna (15–19 Sept) finds that half of adults without diabetes who start taking the weight-loss drug semaglutide in Denmark discontinue treatment within a year.

The Liver King gets fact-checked by MD PhD Doctor
- TMZ Releases Video Of Alleged Kirk Assassin Before Shooting - Mark Tanos
- Dollar Scholar Asks: What’s the Difference Between Cost and Price, and Does It Even Matter?
- Elon Musk's Ambitious Plan: To Send One Million Humans to Mars within the Next Decade - Michael A. Medeiros
- America’s fragile drug supply chain is extremely vulnerable to climate change - Beth Mole
- The Evolution and Impact of Internet Jokes: A Closer Look at Prank.Chat - Bertha Stephens
- The Full Moons of 2024: A Comprehensive Guide to Their Names and Dates - Arya Chandran

Apple’s Thin Phone and Reduced Marketshare – DTH | Daily Tech Headlines
- Representative Democracy and Convoluted Elections - David Lewis Schaefer
- Europe Is Going After America’s Biggest Companies. Trump Must Push Back - Ashley Baker
- Understanding the Leading Causes of End-Stage Multiple Myeloma - Lindsay Curtis
- Mamdani: Democrats' Antisemitism Problem
- iOS 18 Elevates the iPhone with Unmatched Personalization and Intelligence - Michael A. Medeiros
- Nostalgic Sci-Fi Mystery Thriller Is An Overlooked Modern Classic - Robert Scucci